Law360, New York (December 21, 2009, 6:06 PM ET) -- Boehringer Ingelheim International GmbH has moved to dismiss two antitrust suits brought by rival Mylan Inc. and direct buyers that accuse the generics maker of knowingly prosecuting an invalid patent for Parkinson's drug Mirapex, arguing that the suits fail to meet pleading standards under Twombly.
In the U.S. District Court for the Western District of Pennsylvania on Thursday, Boehringer moved to dismiss the suits, which claim it prosecuted a patent for Mirapex it knew to be invalid to suppress the market for generic versions of the...
Boehringer Tries To Derail Mirapex Antitrust Suits
To view the full article, take a free trial now.
